{
    "organizations": [],
    "uuid": "23f5e5af90990d9d5c43e4c2936b293465b5dcdc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kempharm-announces-fda-approval-of/brief-kempharm-announces-fda-approval-of-apadaz-idUSB8N1FK03A",
    "ord_in_thread": 0,
    "title": "BRIEF-Kempharm Announces FDA Approval Of Apadaz",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 23 (Reuters) - Kempharm Inc:\n* KEMPHARM SAYS U.S. FDA APPROVED NDA FOR APADAZ FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE OPIOID ANALGESIC\n* KEMPHARM SAYS U.S. DRUG ENFORCEMENT ADMINISTRATION INDICATED INTENT TO SCHEDULE APADAZ AS A C-II PRODUCT\n* KEMPHARM ANNOUNCES FDA APPROVAL OF APADAZ (BENZHYDROCODONE AND ACETAMINOPHEN) FOR SHORT-TERM MANAGEMENT OF ACUTE PAIN Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-24T03:05:00.000+02:00",
    "crawled": "2018-02-23T21:43:47.025+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "kempharm",
        "inc",
        "kempharm",
        "say",
        "fda",
        "approved",
        "nda",
        "apadaz",
        "management",
        "acute",
        "pain",
        "severe",
        "enough",
        "require",
        "opioid",
        "analgesic",
        "kempharm",
        "say",
        "drug",
        "enforcement",
        "administration",
        "indicated",
        "intent",
        "schedule",
        "apadaz",
        "product",
        "kempharm",
        "announces",
        "fda",
        "approval",
        "apadaz",
        "benzhydrocodone",
        "acetaminophen",
        "management",
        "acute",
        "pain",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}